Pregnancy and childbirth in a woman with homozygous factor V Leiden mutation and thrombosis due to hormonal contraception in a history


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hormonal contraception (HC) has played an enormous role over the past 50 years in providing the basic principles of family planning. However, since the application of HC up to the present time, despite the improved quality of drugs, the lower dose of the estrogen component, and the better quality of the gestagen component, various thrombotic events and future pregnancy complications occur in a number of female patients. The paper describes a clinical case of planning and management of pregnancy and childbirth in a woman with homozygous factor V Leiden mutation, with a history of ileofemoral thrombosis due to the use of HC. In everyday life when the body’s compensatory functions are preserved, homozygous factor V Leiden gene mutation cannot phenotypically manifest itself, but when HC is used, the genetically determined APC-R is added by an acquired form, which creates immediate prerequisites for its phenotypic realization and the risk of thrombosis is increased 80-100-fold. Clarification of these additional conditions and timely diagnosis help effectively prevent the development of diseases and their complications in carriers of gene variants.

Full Text

Restricted Access

About the authors

Nadine M. Khamani

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: nadinka@list.ru
postgraduate student of the Department of Obstetrics and Gynecology №2

Victoria O. Bitsadze

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: gemostasis@mail.ru
MD, professor of the RAS, professor of the Department of Obstetrics and Gynecology №2

Olga Yu. Kaplina

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: dr.kaplina@yandex.ru
researcher, Department of Obstetrics and Gynecology №2

Manolis Papadakis

Hospital Papageorgiou

MD, professor of the Haematology and Hemostasis Unit Saloniki, Greece

Daredzhan L. Kapanadze

Center for Pathology of Pregnancy and Hemostasis

Email: daka.kapanadze@yandex.ru
PhD, director

Alexander D. Makatsaria

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: gemostasis@mail.ru
MD, corresponding member of the RAS, professor, head of the Department of Obstetrics and Gynecology №2

Jamilya H. Khizroeva

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: gemostasis@mail.ru
MD, professor of the Department of Obstetrics and Gynecology №2

Natalya A. Makatsaria

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: gemostasis@mail.ru
PhD, associate professor of the Department of Obstetrics and Gynecology №2

References

  1. Beyer-Westendorf J., Bauersachs R., Hach-Wunderle V., Zotz R.B., Rott H. Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy. Vasa. 2018; 47(6): 441-50. doi: 10.1024/0301-1526/ a000726.
  2. Tricotel A., Raguideau F., Collin C., Zureik M. Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. Pant AB, ed. PLoS One. 2014; 9(4): e93792. doi: 10.1371/journal.pone.0093792. eCollection 2014.
  3. Liatsikos S.A., Tsikouras P., Manav B., Csorba R., von Tempelhoff G.F., Galazio G. Inherited thrombophilia and reproductive disorders. J. Turk. Ger. Gynecol. Assoc. 2016; 17(1): 45-50.
  4. Tormene D., Grandone E., De Stefano V., Tosetto A., Palareti G., Margaglione M. et al. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V. Leiden or prothrombin G20210A mutation. Thromb. Haemost. 2012; 107(3): 477-84. doi: 10.1160/TH11-07-0470.
  5. Peters K., Gordon N., Ricciotti N., Hsieh J., Howard B., Weiss H. Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study. Clin. Exp. Obstet. Gynecol. 2016; 43(3): 334-40.
  6. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J. Thromb. Haemost. 2014; 12(10): 1580-9. doi: 10.1111/jth.12698.
  7. Akinshina S., Makatsariya A., Bitsadze V., Khizroeva J., Khamani N. Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis. J. Perinat. Med. 2018; 46(8): 893-9. doi: 10.1515/jpm-2017-0329.
  8. Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Akinshina S.V. Thromboprophylaxis in pregnant women with a history of thrombophilia and thromboses. Curr. Prog. Obstet. Gynecol. 2013; 1: 11-23.
  9. Hugon-Rodin J., Horellou M.H., Conard J., Gompel A., Plu-Bureau G. Type of combined oral contraceptoves, Factor V. Leiden mutation and risk of venous thromboembolism. Thromb. Haemost. 2018; 118(5): 922-8.
  10. Grimes D.A., Stuart G.S., Levi E.E. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet. Gynecol. 2012; 120(4): 889-95. doi: 10.1097/AOG.0b013e3182699a2b
  11. Dragoman M., Curtis K.M., Gaffield M.E. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception. 2016; 94(3): 280-7. doi: 10.1016/j. contraception.2015.08.002.
  12. Blanco-Molina A. Oral contraception in women with mild thrombophilia: what we have learned recently? Thromb. Res. 2012; 130(Suppl. 1): S16-8. doi: 10.1016/j. thromres.2012.08.263.
  13. Pezeshkpoor B., Castoldi E., Mahler A., Hanel D., Müller J., Hamedani N.S. et al. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn) associated with activated protein C. resistance. J. Thromb. Haemost. 2016; 14(7): 1353-63. doi: 10.1111/jth.13339.
  14. Аганезов С.С., Мороцкая А.В., Аганезова Н.В. Экстренная контрацепция: мнения врачей разных специальностей. Акушерство и гинекология. 2017; 4: 137-43.
  15. Подзолкова Н.М., Колода Ю.А., Коренная В.В., Аксененко В.А., Бакирова Н.Э., Воронцова А.В., Енькова Е.В., Карахалис Л.Ю., Каткова Н.Ю., Минкина Г.Н., Мишарина Е.В., Олина А.А., Сотникова Л.С., Спиридонова Н.В., Ткаченко Л.В., Хачатурян А.Р. Оценка лечебных свойств контрацептивного препарата, содержащего этинилэстрадиол в комбинации с хлормадинона ацетатом. Акушерство и гинекология. 2018; 3: 109-15.
  16. Дубровина С.О., Берлим Ю.Д. Гестагены в терапии эндометриоза. Акушерство и гинекология. 2018; 5: 150-4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies